Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats

Tuguang Kuang, Jun Wang, Baosen Pang, Xiuxia Huang, Elyssa D. Burg, Jason Yuan, Chen Wang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sildenafil, a phosphodiesterase-5 inhibitor, and simvastatin, a cholesterol lowering drug, both have therapeutic effects on PAH; however, the combination of these drugs has not been tested in the treatment of PAH. The purpose of this study was to determine whether the combination of sildenafil and simvastatin is superior to each drug alone in the prevention of MCT-induced PAH. Phosphorylated Smad levels were decreased in lung tissue in MCT-injected rats, whereas ERK protein levels were increased. This indicates a possible role for an increase in mitogenic ERK activity in addition to decreased proapoptotic Smad signaling in the MCT model of PAH. Combination sildenafil and simvastatin treatment prevented the MCT-induced increases in right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH), exerted an anti-proliferative effect on pulmonary artery smooth muscle cells (PASMC). Our results indicate that combination therapy with sildenafil and simvastatin attenuated the development of pulmonary hypertension more than either treatment alone.

Original languageEnglish (US)
Pages (from-to)456-464
Number of pages9
JournalPulmonary Pharmacology and Therapeutics
Volume23
Issue number5
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Monocrotaline
Simvastatin
Polycyclic aromatic hydrocarbons
Pulmonary Hypertension
Rats
Right Ventricular Hypertrophy
Phosphodiesterase 5 Inhibitors
Therapeutic Uses
Ventricular Pressure
Drug Combinations
Pharmaceutical Preparations
Pulmonary Artery
Smooth Muscle Myocytes
Muscle
Cholesterol
Cells
Tissue
Blood Pressure
Lung
Sildenafil Citrate

Keywords

  • Monocrotaline
  • Pulmonary arterial hypertension
  • Sildenafil
  • Simvastatin
  • Vascular remodeling

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. / Kuang, Tuguang; Wang, Jun; Pang, Baosen; Huang, Xiuxia; Burg, Elyssa D.; Yuan, Jason; Wang, Chen.

In: Pulmonary Pharmacology and Therapeutics, Vol. 23, No. 5, 10.2010, p. 456-464.

Research output: Contribution to journalArticle

Kuang, Tuguang ; Wang, Jun ; Pang, Baosen ; Huang, Xiuxia ; Burg, Elyssa D. ; Yuan, Jason ; Wang, Chen. / Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. In: Pulmonary Pharmacology and Therapeutics. 2010 ; Vol. 23, No. 5. pp. 456-464.
@article{f59e810226754c619f954f640c0fff1f,
title = "Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats",
abstract = "Sildenafil, a phosphodiesterase-5 inhibitor, and simvastatin, a cholesterol lowering drug, both have therapeutic effects on PAH; however, the combination of these drugs has not been tested in the treatment of PAH. The purpose of this study was to determine whether the combination of sildenafil and simvastatin is superior to each drug alone in the prevention of MCT-induced PAH. Phosphorylated Smad levels were decreased in lung tissue in MCT-injected rats, whereas ERK protein levels were increased. This indicates a possible role for an increase in mitogenic ERK activity in addition to decreased proapoptotic Smad signaling in the MCT model of PAH. Combination sildenafil and simvastatin treatment prevented the MCT-induced increases in right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH), exerted an anti-proliferative effect on pulmonary artery smooth muscle cells (PASMC). Our results indicate that combination therapy with sildenafil and simvastatin attenuated the development of pulmonary hypertension more than either treatment alone.",
keywords = "Monocrotaline, Pulmonary arterial hypertension, Sildenafil, Simvastatin, Vascular remodeling",
author = "Tuguang Kuang and Jun Wang and Baosen Pang and Xiuxia Huang and Burg, {Elyssa D.} and Jason Yuan and Chen Wang",
year = "2010",
month = "10",
doi = "10.1016/j.pupt.2010.02.003",
language = "English (US)",
volume = "23",
pages = "456--464",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats

AU - Kuang, Tuguang

AU - Wang, Jun

AU - Pang, Baosen

AU - Huang, Xiuxia

AU - Burg, Elyssa D.

AU - Yuan, Jason

AU - Wang, Chen

PY - 2010/10

Y1 - 2010/10

N2 - Sildenafil, a phosphodiesterase-5 inhibitor, and simvastatin, a cholesterol lowering drug, both have therapeutic effects on PAH; however, the combination of these drugs has not been tested in the treatment of PAH. The purpose of this study was to determine whether the combination of sildenafil and simvastatin is superior to each drug alone in the prevention of MCT-induced PAH. Phosphorylated Smad levels were decreased in lung tissue in MCT-injected rats, whereas ERK protein levels were increased. This indicates a possible role for an increase in mitogenic ERK activity in addition to decreased proapoptotic Smad signaling in the MCT model of PAH. Combination sildenafil and simvastatin treatment prevented the MCT-induced increases in right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH), exerted an anti-proliferative effect on pulmonary artery smooth muscle cells (PASMC). Our results indicate that combination therapy with sildenafil and simvastatin attenuated the development of pulmonary hypertension more than either treatment alone.

AB - Sildenafil, a phosphodiesterase-5 inhibitor, and simvastatin, a cholesterol lowering drug, both have therapeutic effects on PAH; however, the combination of these drugs has not been tested in the treatment of PAH. The purpose of this study was to determine whether the combination of sildenafil and simvastatin is superior to each drug alone in the prevention of MCT-induced PAH. Phosphorylated Smad levels were decreased in lung tissue in MCT-injected rats, whereas ERK protein levels were increased. This indicates a possible role for an increase in mitogenic ERK activity in addition to decreased proapoptotic Smad signaling in the MCT model of PAH. Combination sildenafil and simvastatin treatment prevented the MCT-induced increases in right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH), exerted an anti-proliferative effect on pulmonary artery smooth muscle cells (PASMC). Our results indicate that combination therapy with sildenafil and simvastatin attenuated the development of pulmonary hypertension more than either treatment alone.

KW - Monocrotaline

KW - Pulmonary arterial hypertension

KW - Sildenafil

KW - Simvastatin

KW - Vascular remodeling

UR - http://www.scopus.com/inward/record.url?scp=77955413732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955413732&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2010.02.003

DO - 10.1016/j.pupt.2010.02.003

M3 - Article

VL - 23

SP - 456

EP - 464

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 5

ER -